Sage Therapeutics Receives Notification of PDUFA Extension for Zulresso (brexanolone) Injection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2018-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news